国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2013年
12期
2532-2534
,共3页
翼状胬肉%bevacizumab%丝裂霉素C
翼狀胬肉%bevacizumab%絲裂黴素C
익상노육%bevacizumab%사렬매소C
pterygium%bevacizumab%mitomycin C
目的：比较研究翼状胬肉手术联合bevacizumab 与丝裂霉素C的临床疗效及其术后复发率和并发症情况。<br> 方法：将2010-01/2012-01浙江省中西医结合医院眼科住院的翼状胬肉患者80例随机分为两组，A组40例采用手术联合球结膜下注射bevacizumab 治疗，B组40例采用手术联合术中丝裂霉素C贴敷治疗，随访1 a，比较评估两组的临床疗效及其术后复发率和并发症。<br> 结果：A组治愈率为88％， B组为85％，两组临床疗效比较无显著差异（χ2＝0．105，P＞0．05）；A组术后复发率为12％，B组为15％，两组术后复发率比较无显著差异（χ2＝0．105，P＞0．05）；A组术后并发症发生率为2％，B组为18％，两组术后并发症比较有显著差异（χ2＝4．517， P＜0.05）。<br> 结论：翼状胬肉手术联合bevacizumab 与丝裂霉素C的临床疗效显著，术后复发率低，但联合bevacizumab 并发症较少。
目的：比較研究翼狀胬肉手術聯閤bevacizumab 與絲裂黴素C的臨床療效及其術後複髮率和併髮癥情況。<br> 方法：將2010-01/2012-01浙江省中西醫結閤醫院眼科住院的翼狀胬肉患者80例隨機分為兩組，A組40例採用手術聯閤毬結膜下註射bevacizumab 治療，B組40例採用手術聯閤術中絲裂黴素C貼敷治療，隨訪1 a，比較評估兩組的臨床療效及其術後複髮率和併髮癥。<br> 結果：A組治愈率為88％， B組為85％，兩組臨床療效比較無顯著差異（χ2＝0．105，P＞0．05）；A組術後複髮率為12％，B組為15％，兩組術後複髮率比較無顯著差異（χ2＝0．105，P＞0．05）；A組術後併髮癥髮生率為2％，B組為18％，兩組術後併髮癥比較有顯著差異（χ2＝4．517， P＜0.05）。<br> 結論：翼狀胬肉手術聯閤bevacizumab 與絲裂黴素C的臨床療效顯著，術後複髮率低，但聯閤bevacizumab 併髮癥較少。
목적：비교연구익상노육수술연합bevacizumab 여사렬매소C적림상료효급기술후복발솔화병발증정황。<br> 방법：장2010-01/2012-01절강성중서의결합의원안과주원적익상노육환자80례수궤분위량조，A조40례채용수술연합구결막하주사bevacizumab 치료，B조40례채용수술연합술중사렬매소C첩부치료，수방1 a，비교평고량조적림상료효급기술후복발솔화병발증。<br> 결과：A조치유솔위88％， B조위85％，량조림상료효비교무현저차이（χ2＝0．105，P＞0．05）；A조술후복발솔위12％，B조위15％，량조술후복발솔비교무현저차이（χ2＝0．105，P＞0．05）；A조술후병발증발생솔위2％，B조위18％，량조술후병발증비교유현저차이（χ2＝4．517， P＜0.05）。<br> 결론：익상노육수술연합bevacizumab 여사렬매소C적림상료효현저，술후복발솔저，단연합bevacizumab 병발증교소。
AIM: To observe and compare the clinical effect and postoperative recrudescence rate and complication of pterygium surgery combined with bevacizumab or mitomycin C. <br> METHODS: Eighty pterygium inpatients in the Department of Ophthalmology in Integrated Chinese and Western Medicine Hospital of Zhejiang Province from January 2010 to January 2012 were randomly divided into two groups. Forty cases in group A were treated by surgery combined with subconjunctival injection of bevacizumab, Forty cases in group B were treated by surgery combined with mitomycin C sticking therapy. After following up for 1 year, the curative effect and postoperative recurrence rate and complications were compared and evaluated between the two groups. <br> RESULTS: The cure rate of group A and B were 88%, 85%, respectively, demonstrating no significant difference (χ2=0.105, P>0.05);The postoperative recurrence rate of group A, B were 12%, 15%, respectively, the differences of which weren't significantly different (χ2 =0.105, P>0.05); The incidence of postoperative complications in group A, B were 2%, 18%, the differences of which weren't significantly different (χ2=4.517, P<0.05). <br> CONCLUSION: The clinical effect of pterygium surgery combined with bevacizumab or mitomycin C is significant with a low postoperative recrudescence rate, but the former has fewer complications.
